SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001415889-24-024076
Filing Date
2024-09-27
Accepted
2024-09-27 19:31:52
Documents
1
Period of Report
2024-09-27

Document Format Files

Seq Description Document Type Size
1 form4-09272024_110948.html 4  
1 form4-09272024_110948.xml 4 5830
  Complete submission text file 0001415889-24-024076.txt   7333
Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Issuer) CIK: 0001817713 (see all company filings)

IRS No.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O JANUX THERAPEUTICS, INC. 10955 VISTA SORRENTO PARKWAY, SUITE 200 SAN DIEGO CA 92130
Business Address
DiRaimondo Thomas (Reporting) CIK: 0002005618 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-40475 | Film No.: 241336279